Brind.

Ming Hsieh has been appointed as the Chairperson and CEO of Fulgent Genetics.

1 report, 1 independent Updated Aug 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Fulgent Genetics Ming Hsieh

Keep exploring

The entities involved

Fulgent Genetics
biotechnology company
- Surgery Partners, a small-cap healthcare company, operates surgical facilities in the United States.Sun 00:20
Ming Hsieh
American businessman

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 1Business WireFulgent Reports Second Quarter 2025 Financial Results Core Revenue of $81.7 million grows 16% year-over-year Raising Full Year 2025 Core Revenue Guidance to $320 million GAAP gross profit of $34.4 mi